IDENTICAL ANTIMICROBIAL EFFECT OF CEFTRIAXONE AND CEFOTAXIME AMONG DIFFERENT BACTERIAL ISOLATES
Abu El Aish, K., Taleb, M., El Bilbeisi, A. (2023). IDENTICAL ANTIMICROBIAL EFFECT OF CEFTRIAXONE AND CEFOTAXIME AMONG DIFFERENT BACTERIAL ISOLATES. EKB Journal Management System, 46(2), 1249-1258. doi: 10.21608/bfsa.2023.327643
Khaled Abu El Aish; Mahmoud H. Taleb; Abdel Hamid Hassan El Bilbeisi. "IDENTICAL ANTIMICROBIAL EFFECT OF CEFTRIAXONE AND CEFOTAXIME AMONG DIFFERENT BACTERIAL ISOLATES". EKB Journal Management System, 46, 2, 2023, 1249-1258. doi: 10.21608/bfsa.2023.327643
Abu El Aish, K., Taleb, M., El Bilbeisi, A. (2023). 'IDENTICAL ANTIMICROBIAL EFFECT OF CEFTRIAXONE AND CEFOTAXIME AMONG DIFFERENT BACTERIAL ISOLATES', EKB Journal Management System, 46(2), pp. 1249-1258. doi: 10.21608/bfsa.2023.327643
Abu El Aish, K., Taleb, M., El Bilbeisi, A. IDENTICAL ANTIMICROBIAL EFFECT OF CEFTRIAXONE AND CEFOTAXIME AMONG DIFFERENT BACTERIAL ISOLATES. EKB Journal Management System, 2023; 46(2): 1249-1258. doi: 10.21608/bfsa.2023.327643

IDENTICAL ANTIMICROBIAL EFFECT OF CEFTRIAXONE AND CEFOTAXIME AMONG DIFFERENT BACTERIAL ISOLATES

Bulletin of Pharmaceutical Sciences Assiut University
Volume 46, Issue 2, December 2023, Page 1249-1258  XML PDF (954.31 K)
Document Type: Original Article
DOI: 10.21608/bfsa.2023.327643
View on SCiNiTO View on SCiNiTO
Authors
Khaled Abu El Aish email 1; Mahmoud H. Taleb2; Abdel Hamid Hassan El Bilbeisi email orcid 3
1Pharmacy Department, Al Helal Al Emirati Hospital, Palestinnian Ministry of Health, Gaza Strip, Palestine
2Department of Pharmacology and Medical Sciences, Faculty of Pharmacy, Al Azhar University of Gaza, Gaza Strip, Palestine
3Department of Nutrition, School of Medicine and Health Sciences, University of Palestine, Gaza Strip, Palestine
Abstract
Background: This study aimed to screen the antimicrobial-resistant profile of these 3rd generation cephalosporins and to identify their similarity and interchangeability. Method: This cross-sectional study, was conducted in all the government hospitals across the Gaza Strip, Palestine. The study started in November 2017 and continued till December 2022. All clinical samples such as wound swabs (pus), urine, sputum, blood, cerebrospinal fluid (CSF), stool, and others in which ceftriaxone and cefotaxime were examined at the same time were collected from hospitalized patients and outpatient clinic attendants. After the identification of the bacterial isolates, a standard disc diffusion technique for drug susceptibility tests was performed. This study was reviewed and approved by The Palestinian Helsinki Committee. Results: In the current study, 24,120 isolates in which ceftriaxone and cefotaxime were examined at the same time were studied. The predominant organisms isolated were, Escherichia coli 9,720 (40.3%), Klebsiella spp. 5,497 (22.8%), Pseudomonas spp. 2,630 (10.9%), and Staphylococcus aureus 1941 (8.0%). Bacterial isolates showed 57.1% and 57.8% resistance against ceftriaxone and cefotaxime, respectively. In this study, 22,404 (92.9%) bacterial isolates were with identical susceptibility test results to ceftriaxone and cefotaxime. The highest match of susceptibility was seen in Acinetobacter spp. 97.3% (770/791), Klebsiella spp. 95.3% (5,241/5,491), and Escherichia coli 94.9% (9,220/9,720). In Staphylococcus aureus it was 90.6% (1,758/1,941). Conclusion: Ceftriaxone and cefotaxime can be interchangeable in most Enterobacteriaceae bacterial species. Ongoing surveillance of different bacterial antimicrobial resistance and multidrug resistance is strongly recommended together with the consideration of implementing antibiotics stewardship programs in all hospitals.
Keywords
Bacterial isolates; bacterial resistance; cefotaxime; ceftriaxone; multidrug resistance
Statistics
Article View: 120
PDF Download: 148